

Cite this: *Nanoscale Adv.*, 2019, 1, 807

Galactose:PEGamine coated gold nanoparticles adhere to filopodia and cause extrinsic apoptosis†

Konstantina Tzelepi,^a Cristina Espinosa Garcia,^b Phil Williams^b and Jon Golding^{ID}*^a

Ultra-small gold nanoparticles, surface functionalised with a 50 : 50 ratio of a thiolated α -galactose derivative and a thiolated hexaethylene glycol amine, are toxic to HSC-3 oral squamous carcinoma cells. Differences in nanoparticle toxicity were found to be related to the synthesis duration, with 1 h reaction nanoparticles being less toxic than 5 h reaction nanoparticles. The ligand density decreased with longer reaction time, although the size, charge and ligand ratio remained similar. The concentration of sodium borohydride in the reaction decreased logarithmically over 5 h but remained within a concentration range sufficient to desorb weakly bound ligands, possibly explaining the observed gradual decrease in ligand density. Nanoparticle toxicity was abrogated by inhibition of either caspase 3/7 or caspase 8, but not by inhibition of caspase 9, consistent with extrinsic apoptosis. Electron microscopic analysis of cellular uptake demonstrated predominantly cytoplasmic localization. However, when energy-dependent transport was inhibited, by lowering the temperature to 4 °C, a remarkable adhesion of nanoparticles to filopodia was observed. Inhibition of filopodial assembly with a fascin inhibitor prevented nanoparticle adhesion to HSC-3 cells at 4 °C, while fascin inhibition at 37 °C resulted in less cytoplasmic uptake. More adhesion to HSC-3 filopodia was seen with the higher toxicity 5 h reaction time nanoparticles than with the 1 h nanoparticles. By including two further cell types (HaCaT keratinocytes and hCMEC/D3 endothelial cells), a pattern of increasing toxicity with filopodial binding of 5 h reaction nanoparticles became apparent.

Received 3rd October 2018
Accepted 9th November 2018

DOI: 10.1039/c8na00270c

rsc.li/nanoscale-advances

Introduction

Gold nanoparticles (AuNPs) hold enormous promise for delivering a variety of cargoes into cells. However, the details of how different AuNPs interact with and enter cells are still being elucidated.¹

Moreover, some AuNPs exhibit cytotoxicity that does not always correlate directly with AuNP uptake.^{2–4} This cytotoxicity can be useful when targeting cancer cells, but disastrous when targeting delicate or diseased cells to improve their survival or function. The physico-chemical parameters that can affect AuNP uptake and toxicity (without any targeting peptide or antibody ligands) include: nanoparticle size,⁵ charge⁶ and the nature and density of any coating polymers^{7–10} (reviewed by Yah³). Exactly how nanoparticles damage cells remains unclear, but can involve changes to biochemical stress signalling pathways¹¹ and damage to organelles such as mitochondria, lysosomes, and DNA within the nucleus.¹²

We have previously shown that AuNPs coated with a 50 : 50 ratio of α -galactose : PEGamine ligands are efficiently taken up

into kidney and brain endothelial cells, predominantly by energy-dependent mechanisms.¹³ These AuNPs show selective toxicity toward HSC-3 skin cancer cells, compared to a normal keratinocyte cell line (HaCaT) and this toxicity was caspase 3/7-dependent and could be prevented by antioxidants.²

In order to examine the interaction and toxicity of α -galactose:PEGamine AuNPs with HSC-3 cancer cells in more detail, we analysed AuNP distribution on the cell surface, and within the cytoplasm and nucleus. Two types of AuNPs were tested, which differed only in their synthesis time. One was reacted with sodium borohydride for 1 h (short synthesis) and the other was reacted for 5 h (long synthesis). We find that the shorter synthesis time AuNPs show less binding to filopodia and are less toxic.

Materials and methods

Nanoparticle synthesis

2-Thioethyl α -D-galactopyranoside as the disulphide dimer (α -galactose) and 1-thiohexaethylene glycol-17-ammonium acetate (PEG-amine) (both from GalChimia, Spain) were mixed together in a 50 : 50 molar ratio with HAuCl₄ in Milli-Q water with a 3-fold molar excess of total ligands to gold and adjusted to pH 12 with 2 M NaOH. The mixture was stirred constantly and reduced by adding NaBH₄ to 90 mM and samples removed after either 1 h or 5 h. AuNPs were then purified from unreacted ligands and

^aSchool of Life, Health and Chemical Sciences, The Open University, Walton Hall, Milton Keynes, MK7 6AA, UK. E-mail: Jon.Golding@open.ac.uk; Tel: +44 (0)1908 653748

^bMidatech Pharma, 65 Innovation Drive, Milton Park, Abingdon, OX14 4RQ, UK

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8na00270c



reactants *via* five rounds of spin washing with excess Milli-Q water using an Amicon 10 kDa ultrafiltration device. AuNPs were resuspended in water to 2 mg ml⁻¹ [Au] and stored in amber vials at 4 °C. Note that all AuNP concentrations stated in this work are based on gold content.

Sodium borohydride assay

The hydrolytic loss of NaBH₄ during the AuNP synthesis reaction was monitored by the 2,4,6-trinitrobenzenesulfonic acid (TNBS) assay.¹⁴ Milli-Q water was adjusted to pH 12 with 0.2 M NaOH. To a 10 ml portion of this, NaBH₄ was added to achieve a final concentration of 90 mM. To a 5 ml portion of the resulting 90 mM NaBH₄ solution, 15 mg HAuCl₄ and 39 mg 5,5-dithio-bis-(2-nitrobenzoic acid) were simultaneously added, corresponding to the molarities of gold and ligands used in a standard AuNP synthesis reaction (note that we had to replace the α -galactose and PEG-amine disulphide ligands with another disulphide, since TNBS reacts with primary amines). Twenty microlitre aliquots of this reaction mixture were removed at intervals and added to 180 μ l of pH 12 water in 96-well plastic plates. Finally, 20 μ l aliquots of the diluted samples were added to 200 μ l aliquots of freshly prepared 2 mM TNBS in pH 12 water. After 15 min, the absorbance of the TNBS solution was measured at 470 nm using a FLUOstar Optima plate reader (BMG Labtech) and calibrated using a doubling dilution series of the 90 mM NaBH₄ solution, treated in an identical way to the AuNP reaction.

Nanoparticle physico-chemical characterization

TEM. Samples were prepared by drop-coating films of the AuNP solutions on electrostatically discharged carbon-coated copper TEM grids and visualized on a JEM-1400 model EM instrument (JEOL, USA) operated at an accelerating voltage of 80 kV and 100 000 \times magnification. Core sizes were calculated from TEM images using the automated particle analysis feature of ImageJ software and are reported as the mean and median values.

DLS/zeta potential. The hydrodynamic diameter and charge of AuNPs (500 μ g ml⁻¹) were measured using a Zetasizer Nano ZSP (Malvern instruments). DLS measurements were made immediately in pH 7.4 PBS in a ZEN0040 cell, while zeta potential measurements were made in 20 mM of phosphate buffer at pH 7 in a DTS1070 cell.

UV-vis absorbance. Two hundred microlitres of 100–400 μ g ml⁻¹ AuNP solutions in water were measured against a water blank in 96-well plates on a Labtech Spectrostar Nano spectrophotometer. Absorbance was measured between 280 and 800 nm.

FPLC. 0.2 mg ml⁻¹ AuNPs were incubated in PBS for 30 min at 37 °C. Then 20 μ g AuNPs were run on an AKTA Pure FPLC system (GE Healthcare) with a Superdex 200 10/300 GL column at 0.5 ml min⁻¹ isocratic in PBS, using a 100 μ l injection loop and the absorbance monitored at 400 nm.

¹H-NMR. For each sample, 5 mg of AuNPs were transferred into D₂O using ultrafiltration (Amicon Ultra-4, MWCO 10 kDa). Three centrifugation steps were performed in 2 ml D₂O

(4700 rpm, 12 min). After the last centrifugation step, AuNPs were transferred into Eppendorf tubes and dissolved with 0.3 M KCN/0.1 M KOH in D₂O at 37 °C overnight. Samples were then centrifuged at 13 000 \times g for 1 min to remove any insoluble material and analysed by ¹H-NMR at 500 MHz (Avance III HD, Bruker), using MestReNova software. The defining protons for the α -galactose and PEGamine ligands were identified to resonate at 4.95 ppm and 2.75 ppm, respectively. These correspond to the single anomeric proton of α -galactose (NMR doublet) and the two CH₂ protons proximal to the terminal NH₂ group in the PEG-amine linker (NMR triplet).

HPLC. To quantify thiol ligands, 8 μ l of 0.5 mg ml⁻¹ AuNP solution was mixed with 4 μ l of 50 mM tris(2-carboxyethyl) phosphine hydrochloride in water for 10 min at 37 °C at 600 rpm. Then 28 μ l of 25 mM Ellman's reagent in DMSO was added and incubated for a further 60 min at 37 °C at 600 rpm. Samples were transferred to an HPLC vial and 10 μ l of each sample was injected into an Agilent 1260 Infinity HPLC machine with an Ascentis Express peptide ES-C18 column and an acetonitrile/0.1% formic acid solvent gradient, with peak detection at 330 nm. Pure ligands were similarly treated to determine retention times. The HPLC was additionally fitted with an Agilent 6120 Single Quad mass spectrometer to verify peak identities.

SEM-EDS. Three microlitres of 2 mg ml⁻¹ AuNP solutions were dried onto aluminium stubs and analysed with a Zeiss Supra 55VP Field Emission Gun Scanning Electron Microscope (FEGSEM) at 20 kV. EDS analysis was performed with AZtec Energy software (Oxford Instruments). The stubs alone contained undetectable levels of gold and sulphur, 4.9% carbon and 0.5% oxygen. Weight% values for gold, sulphur, carbon and oxygen in the AuNP samples were determined. The calculation of the AuNP ligand density using the sulphur : gold (S : Au) ratio is based on the assumption that each ligand on the AuNP surface carries a single S atom, while Au atoms constitute the AuNP core. The geometry of AuNPs is assumed to be spherical.

Cell culture

HSC-3 squamous carcinoma cells were purchased from the American Type Culture Collection. HaCaT cells were a gift from Erik Walbeem, Erasmus Medical Centre, Rotterdam. Cells were cultured in low glucose (1 g l⁻¹) DMEM media (Gibco) supplemented with 10% FBS (Sigma-Aldrich) and 1% penicillin/streptomycin in a humidified incubator at 37 °C with 5% CO₂. Cells were grown in T-75 culture flasks to about 80% confluency before passage.

Clonogenic assay

Cells were seeded at 300 cells per well in 24-well plates and allowed to adhere overnight. The next day, cells were exposed to AuNPs for 3 h and then washed in fresh medium. We previously demonstrated that 3 h incubation was optimal for clonogenic assay and uptake studies using these types of sugar:PEGamine AuNPs.² Cells were left to grow for 6 days to form colonies and were then stained and fixed with 2% methylene blue in 50% ethanol. Experiments were repeated three times, each with



technical triplicates (total $n = 9$). Images of stained plates were captured using a G:Box Chemi XX6 gel documentation system with GeneSys v1.4.6 software (Syngene). Colonies containing >50 cells were quantified using GeneTools v.4.03 software (Syngene) and expressed as percent of controls. Automated counts were verified by eye. IC_{50} values were estimated from logarithmic plots of AuNP concentration *versus* percent of control colonies.

Cellular uptake and distribution

Cellular uptake was quantified by ICP-MS and TEM.

ICP-MS. Cells were seeded at 30 000 cells per well overnight in 24-well plates. At this density, most cells were isolated from their neighbours. Cells were then incubated with AuNPs for 3 h at a final concentration of $10 \mu\text{g ml}^{-1}$, in triplicate. Cells were washed 3 times in medium, trypsinised and spin washed twice at 2000 rpm in 10 ml PBS. The number of cells in each sample was counted using a haemocytometer prior to the final spin and the cell pellet was dissolved in 1 ml 2% nitric acid for 2 days. Samples were analysed using a Perkin-Elmer NexION 300x ICP-MS with NexION software version 1.4. The gold amount was calculated against a standard curve of gold chloride plus washed cells. The amount of gold per cell was calculated for each sample by dividing the measured gold amount by the cell number.

TEM. 100 000 cells per well were seeded onto 12-well transwell inserts overnight and then incubated with AuNPs for 3 h at a concentration of $10 \mu\text{g ml}^{-1}$. Experiments with HSC-3 cells were repeated three times, each with technical duplicates (total $n = 6$). Experiments with HaCaT cells were technical triplicates. Cells were fixed and AuNPs were silver enhanced for 45 min at room temperature (R-Gent, Aurion, Netherlands) and processed for imaging according to Gromnicova.¹⁵ Ultrathin sections of cells were visualized on a JEOL model 1010 EM instrument operated at an accelerating voltage of 80 kV at $\times 15\ 000$ and $\times 50\ 000$ magnifications. Only isolated cells were counted. It should be noted that silver enhancement increases the size of the nanoparticles, making them easier to detect in cell sections.

Nanoparticle TEM counts on cells

A systematic sampling method was used to evaluate nanoparticle counts in cells. This method was based on acquiring 25 TEM images at the same magnification and same settings across every sample at regular intervals, which included every fifth field of view of a cell. Each image was loaded into ImageJ software (NIH), where the visible areas of the nucleus and cytoplasm, and the length of the cell surface were measured, and the numbers of nanoparticles in each of these three regions were manually counted. Data are expressed as nanoparticles per micron² for nuclear and cytoplasmic nanoparticle counts, and as nanoparticles per micron for cell surface nanoparticle counts.

Fascin inhibition

The fascin inhibitor fascin-G2 (Xcessbio, M60269-2s) was used to inhibit filopodia formation. Cells were incubated with $50 \mu\text{M}$ fascin-G2 for 2 h at 37°C . Then cells were incubated with $10 \mu\text{g ml}^{-1}$ AuNPs in $50 \mu\text{M}$ fascin-G2 for a further 3 h, either at 37°C

or at 4°C . Cells were then washed, fixed and prepared for TEM analysis.

Caspase inhibition

Cells were set up for clonogenic assay as described. Cells were pre-incubated with either 70 nM caspase 8 inhibitor I (Merck, 218773) or 50 nM caspase 9 inhibitor II (Merck, 218776) or caspase 3/7 inhibitor (Abcam, ab120382) for 1 h prior to addition of $10 \mu\text{g ml}^{-1}$ AuNPs and incubation for 3 h. $10 \mu\text{M}$ Anti-mycin A (Abcam, ab141904) was used as a positive control for apoptosis and 50 ng ml^{-1} Apo2 ligand/TRAIL as a positive control for inducing extrinsic apoptosis. Clonogenic assays were analysed after 6 days, as described. Experiments were repeated three times, each with technical triplicates (total $n = 9$).

Statistical analyses

Data were analysed using GraphPad 6.0 Prism software. For cell work, multiple comparisons between many groups were performed by one-way ANOVA with Tukey's multiple comparison post-test; while comparison of the mean values between two groups was made by multiple two-tailed *t*-tests with a Sidak-Bonferroni post-test. Comparison of S : Au ratios, O : Au ratios and C : Au ratios were made using paired two-tailed *t*-tests.

Results and discussion

Physico-chemical and solution stability characterisation

TEM analysis revealed the short synthesis (1 h) and long synthesis (5 h) AuNPs to be spherical with mean core diameters of $1.6 \pm 0.8 \text{ nm}$ and $1.5 \pm 0.9 \text{ nm}$, respectively (mean \pm SD; ESI Fig. 1†). Consistent with this, the UV-vis spectra revealed no plasmon band, indicating a core diameter smaller than 2 nm (ref. 16) (ESI Fig. 2A†). DLS analysis showed a hydrodynamic diameter of $4.6 \pm 0.9 \text{ nm}$ for short synthesis AuNPs and $3.7 \pm 1.0 \text{ nm}$ for long synthesis AuNPs (mean \pm SD; ESI Fig. 2B†). The zeta potential of the AuNPs at pH 7 was positive at $43.8 \pm 16.4 \text{ mV}$ for short synthesis AuNPs (with some split peaks) and $41.8 \pm 10.6 \text{ mV}$ for long synthesis AuNPs (mean \pm SD; ESI Fig. 2C†). FPLC revealed no tendency to aggregate in PBS, with a single elution peak at 17.97 ml for short synthesis AuNPs and at 17.99 ml for long synthesis AuNPs (ESI Fig. 2D†).

¹H-NMR demonstrated an α -galactose : PEGamine ligand ratio of 53 : 47 for short synthesis AuNPs and 51 : 49 for long synthesis AuNPs (ESI Fig. 3†).

SEM-EDS analysis demonstrated a significant $\sim 15\%$ decrease in the S : Au ratio from 0.1013 ± 0.0011 for short synthesis AuNPs to 0.0860 ± 0.0018 for long synthesis AuNPs (mean \pm SD, $P = 0.0001$, $n = 5$ areas analysed per sample; ESI Fig. 4†), consistent with a loss of sulphur-bearing ligands. The ratios of O : Au and C : Au in these analysed regions also significantly decreased with increasing AuNP synthesis time, consistent with a loss of ligands (O : Au 0.1720 ± 0.0035 for short synthesis AuNPs to 0.1414 ± 0.0025 for long synthesis AuNPs; mean \pm SD, $P = 0.0001$, $n = 5$. C : Au 0.3365 ± 0.0091 for short synthesis AuNPs to 0.2819 ± 0.0114 for long synthesis AuNPs; mean \pm SD, $P = 0.0006$, $n = 5$. ESI Fig. 4†).



HPLC analysis similarly demonstrated a loss of ligands from the AuNPs with increasing reaction time (ESI Fig. 5†). Thus, short synthesis AuNPs had 40.8 ligands per 100 Au atoms, while long synthesis AuNPs had 34.8 ligands per 100 Au atoms (a decrease of ~15%, consistent with SEM-EDS). A previous study has determined that 1.52 nm core diameter AuNPs contain an average of 116 Au atoms.¹⁷ This is within the size range of our AuNPs, as determined by TEM. Therefore, the HPLC values of ligands per 100 Au atoms approximate the actual number of ligands per AuNP. Interestingly, our data are similar to those of Jadzinsky *et al.*,¹⁸ in which AuNPs comprising 102 gold atoms were found to be surrounded by 44 thiol (*p*-mercaptobenzoic acid) ligands.

In agreement with our ¹H-NMR data, the HPLC data demonstrated that the α -galactose : PEGamine ligand ratio remained stable during AuNP synthesis (53 : 47 for short synthesis AuNPs and 52 : 48 for long synthesis AuNPs; ESI Fig. 5†).

How are ligands being removed from AuNPs during synthesis? Above a concentration of 24 mM, NaBH₄ has been shown to strip all ligands from readily formed >10 nm AuNPs within 10 min, while at lower NaBH₄ concentrations, desorption becomes less effective (<30% desorption using 8 mM NaBH₄ and no desorption using 0.5 mM NaBH₄).¹⁹ No similar study has examined the kinetics of ligand desorption during AuNP formation. Two ways in which NaBH₄ could be quenched in the reaction are *via* hydrolysis or reaction with disulphide bonds. The former possibility is unlikely, since although NaBH₄ is hydrolysed within seconds at low pH, it is stable for days at high pH and our reaction pH remains alkaline, falling from pH 12 to pH 11.5 in 5 h. The second possibility is that a portion of the NaBH₄ is lost as it reduces the gold salt and the disulphide bonds of the ligands. We therefore measured the NaBH₄ concentration during AuNP synthesis and found that it decreased logarithmically from 90 mM before adding the reactants to 6 mM after 5 h. Importantly, the NaBH₄ concentration fell below 24 mM within 35–40 min (ESI Fig. 6†). However, the same reaction in the absence of disulphides did not demonstrate any dramatic decrease in NaBH₄ concentration for 5 h (not shown). Thus, in our usual synthesis reaction, a low concentration of NaBH₄ persists in solution for several hours and this could set up a dynamic equilibrium between ligand desorption and resorption that favours a slow overall desorption of the more weakly bound ligands from the AuNPs.

Clonogenic assay

The cytotoxic/cytostatic potential of acute (3 h) exposure of HSC-3 cells to AuNPs was determined by clonogenic assay and showed a dose-dependent reduction in cell colonies. Short synthesis AuNPs had an IC₅₀ of around 8 $\mu\text{g ml}^{-1}$, while long synthesis AuNPs had an IC₅₀ of around 3.5 $\mu\text{g ml}^{-1}$ (Fig. 1).

Cellular uptake and distribution of AuNPs

Total cellular uptake of AuNPs, which includes AuNPs both on and within cells, was determined by ICP-MS on low-density cell cultures (to permit the unimpeded extension of filopodia around each cell). Cells were found to accumulate similar




Fig. 1 Clonogenic assay of short synthesis (1 h) and long synthesis (5 h) AuNPs on HSC-3 cells following 3 h acute exposure. All data are shown as mean \pm SEM. ** = $P < 0.01$, *** = $P < 0.001$, $n = 9$.

amounts of each type of AuNP within 3 h (4.8 ± 1.8 pg per cell for short synthesis AuNPs and 6.8 ± 2.2 pg per cell for long synthesis AuNPs; two-tailed *t*-test $P = 0.63$).

To examine the details of AuNP cellular uptake, we used a well-established quantitative TEM method.^{15,20–22} To discriminate between energy-dependent and passive transport, cell uptake studies were performed at 37 °C or 4 °C, respectively. Following 3 h incubation at 37 °C, AuNPs were found predominantly within the cytoplasm, with no significant differences between the accumulation of short synthesis or long synthesis AuNPs (Fig. 2), consistent with the ICP-MS data. However, when incubated instead at 4 °C, there was a dramatic shift in the distribution of both AuNPs to the cell surface, with significantly more long synthesis AuNPs being associated with the cell surface than short synthesis AuNPs (Fig. 3). At 4 °C AuNPs were not randomly distributed on the cell surface, but instead were preferentially associated with filopodia (88.9% (3385/3808) of long synthesis AuNPs and 82.5% (2254/2732) of short synthesis AuNPs at the cell surface were associated with filopodia; Fig. 3B and C).

Previous studies have shown that varying the ligand density affects nanoparticle cellular accumulation, although there is no consensus on whether low or high ligand density is optimal.^{7–10} Moreover, the precise distribution of ligands on the nanoparticle surface may be crucial, since computer simulations indicate that a homogeneous ligand distribution favours cellular uptake, while the presence of ligand-free areas prevents cellular uptake.²³ However, in this study, AuNP intracellular accumulation was not significantly affected by ligand density, although binding to the cell surface was better with lower ligand density AuNPs.

To confirm whether AuNPs were selectively binding to filopodia, HSC-3 cells were pre-incubated with fascin-G2, an inhibitor of the actin bundling ability of fascin, that thereby destabilizes filopodia and prevents their formation. Fascin inhibition resulted in 85% fewer filopodia per micron of the cell surface (compare Fig. 4A and D with Fig. 4B, C, E and F).

Following fascin inhibition, cells loaded with short synthesis or long synthesis AuNPs at 4 °C demonstrated a significant






Fig. 2 TEM images of silver enhanced HSC-3 cells after acute 3 h exposure to $10 \mu\text{g ml}^{-1}$ AuNPs at 37°C . (A) No AuNP control. (B) Short synthesis (1 h) AuNPs. (C) Long synthesis (5 h) AuNPs. (B') and (C') show magnified portions of the boxed regions of (B) and (C), respectively. n = nucleus, cy = cytoplasm, f = filopodia. Scale bars = 500 nm. (D) Quantitation of AuNP counts per micron² for the nucleus and cytoplasm (left axis) and AuNP counts per micron for the cell surface (right axis, bars with red border). Total numbers of AuNPs counted per category are shown on bars. All data are shown as mean \pm SEM, $n = 6$.




Fig. 3 TEM images of silver enhanced HSC-3 cells after acute 3 h exposure to $10 \mu\text{g ml}^{-1}$ AuNPs at 4°C . (A) No AuNP control. (B) Short synthesis (1 h) AuNPs. (C) Long synthesis (5 h) AuNPs. (B') and (C') show magnified portions of the boxed regions of (B) and (C), respectively. n = nucleus, cy = cytoplasm, f = filopodia. Scale bars = 500 nm. (D) Quantitation of AuNP counts per micron² for the nucleus and cytoplasm (left axis) and AuNP counts per micron for the cell surface (right axis, bars with red border). Total numbers of AuNPs counted per category are shown on bars. All data are shown as mean \pm SEM. * = $P < 0.05$, $n = 6$.






Fig. 4 (A–F) TEM images of silver enhanced HSC-3 cells incubated for 3 h with $10 \mu\text{g ml}^{-1}$ AuNPs at 4°C in (A) the absence or (B, C) the presence of a fascin inhibitor or at 37°C in (D) the absence or (E, F) the presence of a fascin inhibitor. Scale bars = 500 nm. (G, H) Quantitation of AuNP counts per μm^2 for the nucleus and cytoplasm (left axis) and AuNP counts per micron for the cell surface (right axis) with or without a fascin inhibitor at either (G) 4°C or (H) 37°C . Total numbers of AuNPs counted per category are shown below bars. All data are shown as mean \pm SEM. * = $P < 0.05$, ** = $P < 0.01$, $n = 6$.

three-fold reduction of AuNPs at the cell surface (Fig. 4G), while cells loaded with short synthesis or long synthesis AuNPs at 37°C demonstrated significantly fewer AuNPs within the cytoplasm (Fig. 4H).

AuNP interactions with other cell lines

In order to determine if there were any obvious trends in the way that long synthesis AuNPs interact with cell membranes, we examined two additional cell types: hCMEC/D3 human endothelial cells and HaCaT human keratinocytes.

First, we examined whether incubation at 4°C resulted in an inhibition of cellular uptake and a redistribution of AuNPs to the cell surface. As shown in Fig. 4, the uptake of $10 \mu\text{g ml}^{-1}$ long synthesis AuNPs into HSC-3 cells is inhibited by 95% if the

incubation is performed at 4°C (mean cytoplasmic AuNPs: $5.97 \pm 1.97/\mu\text{m}^2$ at 37°C versus $0.28 \pm 0.12/\mu\text{m}^2$ at 4°C , Fig. 4G and H). The accumulation of $10 \mu\text{g ml}^{-1}$ long synthesis AuNPs into HaCaT cells was similarly inhibited by 94% when the incubation was performed at 4°C (mean cytoplasmic AuNPs: $7.39 \pm 1.02/\mu\text{m}^2$ at 37°C versus $0.43 \pm 0.12/\mu\text{m}^2$ at 4°C ; ESI Fig. 7A and B†). Finally, under conditions comparable to those used here, we previously reported that the accumulation of $8 \mu\text{g ml}^{-1}$ long synthesis AuNPs into hCMEC/D3 cells for 3 h is inhibited by 98% if the incubation is instead performed at 4°C .¹³

Next, we focussed on the proportion of long synthesis AuNPs associated with filopodia on the cell surface at 4°C . As mentioned above, HSC-3 cells exhibit 88.9% association of AuNPs with filopodia at 4°C (3385 AuNPs on filopodia of 3808



total AuNPs on the cell surface). In contrast, HaCaT cells exhibit 52.5% association of AuNPs with filopodia at 4 °C (519 AuNPs on filopodia of 988 total AuNPs on the cell surface, ESI Fig. 7B†). A novel re-analysis of our existing TEM data for hCMEC/D3 cells at 4 °C (ref. 13) showed 11.9% association of AuNPs with filopodia (78 AuNPs on filopodia of 657 total AuNPs on the cell surface, ESI Fig. 7C and D†).

From this limited dataset, it is possible to see a trend whereby the proportion of AuNPs associated with filopodia on the cell surface correlates with toxicity. Thus, HSC-3: 88.9% filopodia binding, IC_{50} 3.5 $\mu\text{g ml}^{-1}$; HaCaT: 52.5% filopodia binding, IC_{50} 10 $\mu\text{g ml}^{-1}$ (ESI Fig. 7E†); and hCMEC/D3: 11.9% filopodia binding, $IC_{50} > 75 \mu\text{g ml}^{-1}$ (note that hCMEC/D3 does not grow clonogenically). However, AuNPs were non-toxic at 75 $\mu\text{g ml}^{-1}$ after continuous exposure for 48 h (ref. 13). These data suggest that filopodial binding may stimulate cell death receptor(s), and this possibility is further explored in the next section using HSC-3 cells.

This is the first unequivocal report of AuNPs interacting specifically with filopodia. On macrophages, bacterial particles are captured by the shaft of the filopodia and then directed towards the cell surface into phagocytic cups.²⁴ Similarly, exosome nanovesicles attach to filopodia and become directed to endocytic hotspots at their base.²⁵ AuNPs were only seen on filopodia at 4 °C when energy-dependent transport was inhibited; this suggests that at 37 °C they are normally rapidly cleared and/or endocytosed. However, we have no evidence that the extent of filopodial binding is a predictor of subsequent uptake: they could be independent.

We cannot yet definitively state whether AuNPs initially bind to pre-existing filopodia or whether AuNP binding to the cell surface locally stimulates filopodia formation. A study involving silica nanoparticles found that the nanoparticle aspect ratio affected filopodia formation and pinocytosis.²⁶

One possibility is that these AuNPs are capable of binding to receptors expressed preferentially on filopodia, possibly in an analogous manner to the selective cancer cell targeting of some oncolytic viruses.²⁷

Another possibility is that electrostatic interactions may occur between the positively charged AuNPs and the negatively charged cell membrane.^{28,29} Selectivity could arise due to variations in membrane potential, which can differ by up to 90 mV between different cell types.²⁸ It is currently unknown whether the membrane potential of filopodia is more negative than that of the other regions of the cell membrane. However, the curvature of the filopodial shaft is sculpted from within by negative charges on the convex surface of small, 'banana-shaped' intracellular proteins, which repel and bend the adjacent negatively charged cell membrane.³⁰ Speculatively, this may locally increase the negative charge on the filopodia surface. Consistent with this idea, positively charged 1.4 nm "Nanogold" AuNPs appear to bind to filopodia more strongly than the rest of the cell membrane on fixed COS7 cells.³¹ Although the magnification used in that SEM study was unable to resolve individual AuNPs. The exact nature of the ligand shell on nanogold is proprietary, but the manufacturer states there are 6 primary amine groups per AuNP.³² This differs from the ligand structure of our AuNPs, disfavoured (but not disproving) the idea of

a common filopodial receptor for both types of AuNPs and instead favouring the idea of an electrostatic contribution to AuNP binding to cell surfaces, with the exact distribution of AuNPs on each cell surface being determined by charge heterogeneities.

Independent of AuNP charge, the energy-independent insertion of AuNPs coated in amphiphilic organic ligands into the cell membrane lipid bilayer occurs preferentially in regions of high cell membrane curvature³³ and is dramatically improved when the core size is below 3 nm.³⁴ Although these studies did not specifically examine filopodia, the tips and bases of filopodial protrusions and the small radius of the filopodial shaft all constitute highly curved regions of the cell membrane and could therefore act as preferential adhesion sites for nanoparticles capable of this kind of membrane insertion *via* 'snorkeling'.³⁵ In the present study, the hexaethylene glycol portion of the PEGamine ligand may be sufficiently amphiphilic to allow such an energy-independent interaction with the cell membrane. Further detailed studies will be required to compare the filopodial binding and cellular uptake of AuNPs using different ratios of α -galactose : PEGamine. Our previous study² demonstrated differences in uptake (assessed by ICP-MS) into HSC-3 and HaCaT cells as the α -galactose : PEGamine ratio was varied. The highest uptake being seen with 50 : 50 ratio AuNPs (50 : 50 > 60 : 40 \approx 40 : 60 \approx 0 : 100 > 100 : 0). However, we do not yet have any TEM data regarding the filopodial interactions of these different α -galactose : PEGamine ratio AuNPs under energy-independent conditions, such as incubation at 4 °C, and we have found no similar TEM study in the literature.

AuNP toxicity is due to extrinsic apoptosis

These studies were done using the more toxic, long synthesis AuNPs. Co-incubation of HSC-3 cells with AuNPs and a caspase 3/7 inhibitor prevented AuNP-induced cell death in clonogenic assays, confirming apoptosis (Fig. 5A).

To discriminate between classical caspase-dependent extrinsic and intrinsic apoptosis pathways, cells were co-incubated with AuNPs and either a caspase 8 inhibitor (apical caspase in the extrinsic pathway) (Fig. 5B) or a caspase 9 inhibitor (apical caspase in the intrinsic pathway) (Fig. 5C).³⁶ Caspase 9 inhibition had no effect on AuNP toxicity, while caspase 8 inhibition prevented AuNP toxicity, suggesting extrinsic apoptosis. In each case, cell death due to positive control apoptosis-inducing agents was prevented by the caspase inhibitors (Fig. 5). Note that each caspase inhibitor alone is slightly toxic and rescue of AuNP or positive control drug toxicity brings the cell viability back to the inhibitor-only value.

Nanoparticle toxicity,³⁷ specifically AuNP toxicity,³⁸ is usually reported to occur *via* mitochondrial³⁷ or endoplasmic reticulum stress,³⁹ leading to cleavage of caspase 9.^{38,40} By contrast, nanoparticle-induced extrinsic apoptosis, due to caspase 8 cleavage, is rarely reported. Cleavage of caspase 8 and accumulation of FADD were seen in JB6 mouse skin cells within 1 h of adding tungsten carbide-cobalt nanoparticles,⁴¹ while cleavage of caspase 8 was seen in human keratinocyte HaCaT cells within 6 h of adding titanium dioxide nanoparticles.⁴²






Fig. 5 Clonogenic assays of HSC-3 cells treated with long synthesis time AuNPs or apoptosis-inducing drugs and inhibitors of (A) caspase 3/7 or (B) caspase 8 or (C) caspase 9. All are data shown as mean \pm SEM. ns = not significant. * = $P < 0.05$, ** = $P < 0.01$, $n = 9$.

However, to our knowledge, extrinsic apoptosis has not been reported before with AuNPs. We do not claim that there is anything particularly unusual about our AuNPs that leads to

extrinsic apoptosis, simply that most papers demonstrating AuNP-induced apoptosis only look at caspase 3 activation (reviewed in ref. 38).

It is tempting to link our observations of increased filopodial binding of AuNPs with extrinsic apoptosis. However, our data do not yet allow us to conclude that excessive filopodial binding causes apoptosis. Future work will determine whether these, currently independent, observations are linked.

For instance, it is not known whether any of the death receptors (TNFr, TRAMP, Fas, or DRs 4 to 6),⁴³ which locally cleave and activate caspase 8, are concentrated within filopodia and could thereby become activated by excessive or prolonged AuNP binding. It is nonetheless intriguing that increased filopodial density is often reported in cancer cells,⁴⁴ being important for tumour progression, migration and dissemination.^{44,45} Moreover, caspase 8 is associated with cell migration in cancer cells,⁴⁶ being specifically associated with focal adhesion complexes,⁴⁷ raising the possibility that caspase 8 may also be concentrated within filopodia.

Once inside cells, AuNPs can damage or impair the function of various organelles (reviewed in ref. 48), including lysosomes,⁴⁹ mitochondria⁵⁰ and the nucleus.¹² AuNPs can also activate metal exposure and oxidative stress signalling pathways,¹¹ resulting in autophagy.⁵¹

AuNP-induced cell death is therefore likely to be multifactorial, with distinct temporal sequences of events converging *via* several pathways to kill the cell.

Conclusions

We have identified that 50 : 50 α -galactose : PEGamine AuNPs accumulate to differing extents on the filopodia of various cell types when energy-dependent uptake is prevented. These data provide a fascinating insight into how AuNPs initially interact with cell membranes and how the extent of filopodial interaction may be a deciding factor in the initiation of extrinsic death pathways. It will now be important to survey a large number of normal and diseased cell types to determine whether there is a correlation between how AuNPs interact with cell membranes and resulting cell behaviours, not limited to cell death.

Nanoparticle synthesis time is rarely reported in the literature. Our observation that longer synthesis time AuNPs are more adherent to HSC-3 cell membranes and are more toxic than short synthesis AuNPs underscores that future publications would be wise to routinely quote synthesis time.

From a practical perspective, our data suggest that by varying the synthesis time, AuNPs could be engineered for either enhanced or reduced toxicity, depending on the desired application.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Konstantina Tzelepi was funded by a joint grant from Midatech Pharma and the Open University. We thank Dr Radka



Gromnicova and Gordon Imlach at the Open University for preparing sections for TEM and performing SEM-EDS, respectively. We additionally thank Dr Radka Gromnicova and Professor David Male at the Open University for sharing unpublished TEM images of hCMEC/D3 cells.

References

- 1 S. Behzadi, V. Serpooshan, W. Tao, M. A. Hamaly, M. Y. Alkawareek, E. C. Dreaden, D. Brown, A. M. Alkilany, O. C. Farokhzad and M. Mahmoudi, *Chem. Soc. Rev.*, 2017, **46**, 4218–4244.
- 2 S. Grellet, K. Tzelepi, M. Roskamp, P. Williams, A. Sharif, R. Slade-Carter, P. Goldie, N. Whilde, M. A. Smialek, N. J. Mason and J. P. Golding, *PLoS One*, 2017, **12**, e0181103.
- 3 C. S. Yah, *Biomed. Res.*, 2013, **24**, 400–413.
- 4 A. M. Alkilany and C. J. Murphy, *J. Nanopart. Res.*, 2010, **12**, 2313–2333.
- 5 B. D. Chithrani, A. A. Ghazani and W. C. W. Chan, *Nano Lett.*, 2006, **6**, 662–668.
- 6 C. M. Goodman, C. D. McCusker, T. Yilmaz and V. M. Rotello, *Bioconjugate Chem.*, 2004, **15**, 897–900.
- 7 T. Lund, M. F. Callaghan, P. Williams, M. Turmaine, C. Bachmann, T. Rademacher, I. M. Roitt and R. Bayford, *Biomaterials*, 2011, **32**, 9776–9784.
- 8 H. Liu, T. L. Doane, Y. Cheng, F. Lu, S. Srinivasan, J.-J. Zhu and C. Burda, *Part. Part. Syst. Charact.*, 2015, **32**, 197–204.
- 9 D. R. Elias, A. Poloukhine, V. Popik and A. Tsourkas, *Nanomedicine*, 2013, **9**, 194–201.
- 10 D. H. M. Dam, R. C. Lee and T. W. Odom, *Nano Lett.*, 2014, **14**, 2843–2848.
- 11 E. Bajak, M. Fabbri, J. Ponti, S. Gioria, I. Ojea-Jiménez, A. Collotta, V. Mariani, D. Gilliland, F. Rossi and L. Gribaldo, *Toxicol. Lett.*, 2015, **233**, 187–199.
- 12 M. Tsoli, H. Kuhn, W. Brandau, H. Esche and G. Schmid, *Small*, 2005, **1**, 841–844.
- 13 R. Gromnicova, M. Kaya, I. A. Romero, P. Williams, S. Satchell, B. Sharrack and D. Male, *PLoS One*, 2016, **11**, e0161610.
- 14 B. Elamin and G. E. Means, *Anal. Chim. Acta*, 1979, **107**, 405–409.
- 15 R. Gromnicova, H. A. Davies, P. Sreekanthreddy, I. A. Romero, T. Lund, I. M. Roitt, J. B. Phillips and D. K. Male, *PLoS One*, 2013, **8**, e81043.
- 16 G. L. Nealon, B. Donnio, R. Greget, J.-P. Kappler, E. Terazzi and J.-L. Gallani, *Nanoscale*, 2012, **4**, 5244.
- 17 M. J. Hostetler, J. E. Wingate, C.-J. Zhong, J. E. Harris, R. W. Vachet, M. R. Clark, J. D. Londono, S. J. Green, J. J. Stokes, G. D. Wignall, G. L. Glish, M. D. Porter, N. D. Evans and R. W. Murray, *Langmuir*, 1998, **14**, 17–30.
- 18 P. D. Jadzinsky, G. Calero, C. J. Ackerson, D. A. Bushnell and R. D. Kornberg, *Science*, 2007, **318**, 430–433.
- 19 S. M. Ansar, F. S. Ameer, W. Hu, S. Zou, C. U. Pittman and D. Zhang, *Nano Lett.*, 2013, **13**, 1226–1229.
- 20 A. Elsaesser, C. A. Barnes, G. McKerr, A. Salvati, I. Lynch, K. A. Dawson and C. V. Howard, *Nanomedicine*, 2011, **6**, 1189–1198.
- 21 A. P. Brown, R. M. D. Brydson and N. S. Hondow, *J. Phys.: Conf. Ser.*, 2014, **522**, 012058.
- 22 B. Rothen-Rutishauser, D. A. Kuhn, Z. Ali, M. Gasser, F. Amin, W. J. Parak, D. Vanhecke, A. Fink, P. Gehr and C. Brandenberger, *Nanomedicine*, 2014, **9**, 607–621.
- 23 V. Schubertová, F. J. Martinez-Veracoechea and R. Vácha, *Soft Matter*, 2015, **11**, 2726–2730.
- 24 M. Horsthemke, A. C. Bachg, K. Groll, S. Moyzio, B. Mütter, S. A. Hemkemeyer, R. Wedlich-Söldner, M. Sixt, S. Tacke, M. Bähler and P. J. Hanley, *J. Biol. Chem.*, 2017, **292**, 7258–7273.
- 25 W. Heusermann, J. Hean, D. Trojer, E. Steib, S. von Bueren, A. Graff-Meyer, C. Genoud, K. Martin, N. Pizzato, J. Voshol, D. V. Morrissey, S. E. L. Andaloussi, M. J. Wood and N. C. Meisner-Kober, *J. Cell Biol.*, 2016, **213**, 173–184.
- 26 H. Meng, S. Yang, Z. Li, T. Xia, J. Chen, Z. Ji, H. Zhang, X. Wang, S. Lin, C. Huang, Z. H. Zhou, J. I. Zink and A. E. Nel, *ACS Nano*, 2011, **5**, 4434–4447.
- 27 P. K. Singh, J. Doley, G. R. Kumar, A. P. Sahoo and A. K. Tiwari, *Indian J. Med. Res.*, 2012, **136**, 571–584.
- 28 M. Yang and W. J. Brackenbury, *Front. Physiol.*, 2013, **4**, 185.
- 29 E. C. Cho, J. Xie, P. A. Wurm and Y. Xia, *Nano Lett.*, 2009, **9**, 1080–1084.
- 30 S. H. Lee, F. Kerff, D. Chereau, F. Ferron, A. Klug and R. Dominguez, *Structure*, 2007, **15**, 145–155.
- 31 H. Nishiyama, K. Teramoto, M. Suga and C. Sato, *Microsc. Res. Tech.*, 2014, **77**, 153–160.
- 32 Positively charged nanogold (product 2022) Nanoprobes.com, <http://www.nanoprobes.com/instructions/Inf2022.html>, accessed 20 June 2018.
- 33 R. C. Van Lehn, M. Ricci, P. H. J. Silva, P. Andreozzi, J. Reguera, K. Voitchovsky, F. Stellacci and A. Alexander-Katz, *Nat. Commun.*, 2014, **5**, 4482.
- 34 R. C. Van Lehn, P. U. Atukorale, R. P. Carney, Y.-S. Yang, F. Stellacci, D. J. Irvine and A. Alexander-Katz, *Nano Lett.*, 2013, **13**, 4060–4067.
- 35 A. K. Chamberlain, Y. Lee, S. Kim and J. U. Bowie, *J. Mol. Biol.*, 2004, **339**, 471–479.
- 36 S. Elmore, *Toxicol. Pathol.*, 2007, **35**, 495–516.
- 37 D.-D. Ma and W.-X. Yang, *Oncotarget*, 2016, **7**, 40882–40903.
- 38 H. Sun, J. Jia, C. Jiang and S. Zhai, *Int. J. Mol. Sci.*, 2018, **19**, 754.
- 39 C. Noël, J.-C. Simard and D. Girard, *Toxicol. Vitro*, 2016, **31**, 12–22.
- 40 N. Morishima, K. Nakanishi, H. Takenouchi, T. Shibata and Y. Yasuhiko, *J. Biol. Chem.*, 2002, **277**, 34287–34294.
- 41 J. Zhao, J. Zhao, L. Bowman, L. Bowman, R. Magaye, R. Magaye, S. S. Leonard, S. S. Leonard, V. Castranova, V. Castranova, M. Ding and M. Ding, *Int. J. Oncol.*, 2013, **42**, 1349–1359.
- 42 C. Wright, A. K. V. Iyer, L. Wang, N. Wu, J. S. Yakisich, Y. Rojanasakul and N. Azad, *Drug Chem. Toxicol.*, 2017, **40**, 90–100.
- 43 H. Walczak, *Cold Spring Harbor Perspect. Biol.*, 2013, **5**, a008698.
- 44 A. Arjonen, R. Kaukonen and J. Ivaska, *Cell Adhes. Migr.*, 2011, **5**, 421–430.



- 45 G. Jacquemet, H. Hamidi and J. Ivaska, *Curr. Opin. Cell Biol.*, 2015, **36**, 23–31.
- 46 R. P. Graf, N. Keller, S. Barbero and D. Stupack, *Curr. Mol. Med.*, 2014, **14**, 246–254.
- 47 S. Barbero, A. Mielgo, V. Torres, T. Teitz, D. J. Shields, D. Mikolon, M. Bogyo, D. Barilà, J. M. Lahti, D. Schlaepfer and D. G. Stupack, *Cancer Res.*, 2009, **69**, 3755–3763.
- 48 M. Kодиha, Y. M. Wang, E. Hutter, D. Maysinger and U. Stochaj, *Theranostics*, 2015, **5**, 357–370.
- 49 X. Ma, Y. Wu, S. Jin, Y. Tian, X. Zhang, Y. Zhao, L. Yu and X.-J. Liang, *ACS Nano*, 2011, **5**, 8629–8639.
- 50 Y. Pan, A. Leifert, D. Ruau, S. Neuss, J. Bornemann, G. Schmid, W. Brandau, U. Simon and W. Jahnen-Dechent, *Small*, 2009, **5**, 2067–2076.
- 51 J. J. Li, D. Hartono, C.-N. Ong, B.-H. Bay and L.-Y. L. Yung, *Biomaterials*, 2010, **31**, 5996–6003.

